Hemispherx Misled Investors Over Anti-Fatigue Drug, Suit Says
Hemispherx Biopharma Inc.'s directors and officers were hit with a shareholder derivative suit in Pennsylvania court Tuesday alleging they misrepresented the safety and efficacy of the anti-fatigue drug Ampligen and overstated...To view the full article, register now.
Already a subscriber? Click here to view full article